Keywords: InterMune, Esbriet, Idiopathic Pulmonary fibrosis, Germany, IQWIG, AMNOG

Germany’s IQWIG negative on InterMune’s Esbriet

Article | 18 December 2011

Print This

US biotech firm InterMune (Nasdaq: ITMN) says that Germany’s private Institute for Quality and Efficiency in Health Care ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in